China approves GSK's Cervarix

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said China FDA approved Cervarix to prevent cervical cancer. GSK said Cervarix is the first HPV vaccine approved in China.

In early 2017, the company expects to launch the HPV types 16 and 18 vaccine formulated with adjuvant AS04. GSK did not respond to inquiries regarding price. ...